Company intelligence / Profile preview

Neuvosyn Laboratories

Alpharetta, Georgia, United Statesaccessdata.fda.gov ↗

Ownership: Private
Development stage: Other

Overview

Neuvosyn Laboratories developed and received FDA approval for Balcoltra, a fixed-dose combination oral contraceptive containing levonorgestrel, ethinyl estradiol, and ferrous bisglycinate. The product is registered for the prevention of pregnancy. No additional clinical results or pipeline programs are publicly disclosed.

Therapeutic areas: Women's Health
Modalities: Small moleculeHormone (specifically estrogenic and progestogenic steroids)
Industry: Biotech

Partnerships

Avion Pharmaceuticals (co-development/commercialization partner for Balcoltra)

Beyond the preview

Go deeper on Neuvosyn Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuvosyn Laboratories.

Explore the full profile